Genentech Reports Update on Phase III SKYSCRAPER-01 Study Results
Genentech announces that its Phase III SKYSCRAPER-01 study, testing tiragolumab combined with Tecentriq versus Tecentriq alone in PD-L1-high non-small cell lung cancer (NSCLC) patients, did not meet its primary endpoint of overall survival. The global, randomized, double-blinded study involved 534 previously untreated patients with locally advanced unresectable or metastatic NSCLC. While the safety profile remained consistent with no new signals identified, detailed data will be presented at a medical meeting in 2025. The company plans to review its study programs and expects additional Phase III data across different settings next year.
Genentech annuncia che il suo studio di Fase III SKYSCRAPER-01, che testa tiragolumab combinato con Tecentriq rispetto a Tecentriq da solo in pazienti con cancro polmonare non a piccole cellule con alta espressione di PD-L1 (NSCLC), non ha raggiunto il suo obiettivo principale di sopravvivenza globale. Lo studio globale, randomizzato e in doppio cieco ha coinvolto 534 pazienti precedentemente non trattati con NSCLC localmente avanzato, irresecabile o metastatico. Sebbene il profilo di sicurezza sia rimasto costante senza nuovi segnali identificati, i dati dettagliati saranno presentati in un incontro medico nel 2025. L'azienda prevede di rivedere i suoi programmi di studio e si aspetta dati aggiuntivi di Fase III in diversi contesti l'anno prossimo.
Genentech anuncia que su estudio de Fase III SKYSCRAPER-01, que prueba tiragolumab combinado con Tecentriq frente a Tecentriq solo en pacientes con cáncer de pulmón de células no pequeñas con alta expresión de PD-L1 (NSCLC), no alcanzó su objetivo primario de supervivencia general. El estudio global, aleatorizado y doble ciego involucró a 534 pacientes previamente no tratados con NSCLC localmente avanzado, irresecable o metastásico. Si bien el perfil de seguridad se mantuvo consistente sin nuevas señales identificadas, los datos detallados se presentarán en una reunión médica en 2025. La compañía planea revisar sus programas de estudio y espera datos adicionales de Fase III en diferentes contextos el próximo año.
제넨텍은 tiragolumab과 Tecentriq을 병합하여 PD-L1 고발현 비소세포 폐암 (NSCLC) 환자에서 Tecentriq 단독과 비교하는 Phase III SKYSCRAPER-01 연구가 전반적인 생존율이라는 주요 목표를 달성하지 못했다고 발표했습니다. 이 글로벌, 무작위, 이중 맹검 연구는 수술이 불가능하거나 전이된 NSCLC 환자 534명을 대상으로 진행되었습니다. 안전성 프로파일은 변함이 없고 새로운 신호도 확인되지 않았으며, 상세한 데이터는 2025년 의학 회의에서 발표될 예정입니다. 회사는 연구 프로그램을 검토하고 내년에는 다양한 환경에서 추가 Phase III 데이터를 기대하고 있습니다.
Genentech annonce que son étude de Phase III SKYSCRAPER-01, testant tiragolumab combiné avec Tecentriq par rapport à Tecentriq seul chez des patients atteints de cancer du poumon non à petites cellules avec une forte expression de PD-L1 (NSCLC), n'a pas atteint son objectif principal de survie globale. L'étude mondiale, randomisée et en double aveugle a impliqué 534 patients précédemment non traités atteints de NSCLC localement avancé, irrésecable ou métastatique. Bien que le profil de sécurité soit demeuré constant, sans nouveaux signaux identifiés, des données détaillées seront présentées lors d'une réunion médicale en 2025. L'entreprise prévoit de revoir ses programmes d'études et s'attend à des données supplémentaires de Phase III dans différents contextes l'année prochaine.
Genentech kündigt an, dass die Phase-III-Studie SKYSCRAPER-01, die tiragolumab in Kombination mit Tecentriq im Vergleich zu Tecentriq allein bei Patienten mit PD-L1-hohem nicht-kleinzelligem Lungenkrebs (NSCLC) testet, ihr primäres Ziel der Gesamtüberlebensrate nicht erreicht hat. Die globale, randomisierte, doppelblinde Studie umfasste 534 zuvor unbehandelte Patienten mit lokal fortgeschrittenem, nicht resektablem oder metastasiertem NSCLC. Während das Sicherheitsprofil konstant blieb und keine neuen Signale identifiziert wurden, werden detaillierte Daten bei einer medizinischen Konferenz im Jahr 2025 präsentiert. Das Unternehmen plant, seine Studienprogramme zu überprüfen und erwartet im nächsten Jahr zusätzliche Phase-III-Daten aus verschiedenen Settings.
- Safety profile remained consistent with no new safety signals
- Failed to meet primary endpoint of overall survival in Phase III SKYSCRAPER-01 study
- Potential setback for tiragolumab/Tecentriq combination therapy in NSCLC treatment
SKYSCRAPER-01 is a global Phase III, randomized, double-blinded study evaluating tiragolumab plus Tecentriq compared to Tecentriq alone in 534 patients with PD-L1-high previously untreated, locally advanced unresectable or metastatic NSCLC. Patients were randomized 1:1 to receive either tiragolumab plus Tecentriq or placebo plus Tecentriq, until disease progression, loss of clinical benefit, or unacceptable toxicity. The study did not reach the primary endpoint of overall survival at the final analysis. The overall safety profile observed remained consistent with longer follow-up, and no new safety signals were identified. The detailed data will be presented at a medical meeting in 2025.
Genentech continuously reviews its study programs to determine if any adjustments are necessary for the purposes of ongoing research. Genentech will apply the same principles to this program, with additional data from Phase III studies across different settings or tumor types anticipated next year.
About tiragolumab
Tiragolumab is an investigational immune checkpoint inhibitor with an intact Fc region. Tiragolumab selectively binds to TIGIT, a novel inhibitory immune checkpoint which suppresses the immune response to cancer.
About Tecentriq® (atezolizumab)
Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells.
Tecentriq
Tecentriq is a prescription medicine used to treat adults with:
Adults with a type of lung cancer called non-small cell lung cancer (NSCLC).
-
Tecentriq may be used alone as a treatment for their lung cancer:
- to help prevent their lung cancer from coming back after their tumor(s) has been removed by surgery and they have received platinum-based chemotherapy, and
- they have stage 2 to 3A NSCLC (patients should talk to their healthcare provider about what these stages mean), and
- their cancer tests positive for “PD-L1.”
-
Tecentriq may be used alone as their first treatment when their lung cancer:
- has spread or grown, and
- their cancer tests positive for “high PD-L1,” and
- their tumor does not have an abnormal “EGFR” or “ALK” gene.
-
Tecentriq may be used with the medicines bevacizumab, paclitaxel, and carboplatin as their first treatment when their lung cancer:
- has spread or grown, and
- is a type called “non-squamous NSCLC,” and
- their tumor does not have an abnormal “EGFR” or “ALK” gene.
-
Tecentriq may be used with the medicines paclitaxel protein-bound and carboplatin as their first treatment when their lung cancer:
- has spread or grown, and
- is a type called “non-squamous NSCLC,” and
- their tumor does not have an abnormal “EGFR” or “ALK” gene.
-
Tecentriq may be used alone when their lung cancer:
- has spread or grown, and
- if they have tried chemotherapy that contains platinum, and it did not work or is no longer working.
- if their tumor has an abnormal “EGFR” or “ALK” gene, they should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.
It is not known if Tecentriq is safe and effective when used in children for the treatment of NSCLC.
Important Safety Information
What is the most important information about Tecentriq?
Tecentriq can cause the immune system to attack normal organs and tissues in any area of the body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. Patients can have more than one of these problems at the same time. These problems may happen anytime during their treatment or even after their treatment has ended.
Patients should call or see their healthcare provider right away if they develop any new or worse signs or symptoms, including:
Lung problems
- cough
- shortness of breath
- chest pain
Intestinal problems
- diarrhea (loose stools) or more frequent bowel movements than usual
- stools that are black, tarry, sticky, or have blood or mucus
- severe stomach-area (abdomen) pain or tenderness
Liver problems
- yellowing of the skin or the whites of the eyes
- severe nausea or vomiting
- pain on the right side of their stomach area (abdomen)
- dark urine (tea colored)
- bleeding or bruising more easily than normal
Hormone gland problems
- headaches that will not go away or unusual headaches
- eye sensitivity to light
- eye problems
- rapid heartbeat
- increased sweating
- extreme tiredness
- weight gain or weight loss
- feeling more hungry or thirsty than usual
- urinating more often than usual
- hair loss
- feeling cold
- constipation
- their voice gets deeper
- dizziness or fainting
- changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness
Kidney problems
- decrease in their amount of urine
- blood in their urine
- swelling of their ankles
- loss of appetite
Skin problems
- rash
- itching
- skin blistering or peeling
- painful sores or ulcers in mouth or nose, throat, or genital area
- fever or flu-like symptoms
- swollen lymph nodes
Problems can also happen in other organs.
These are not all of the signs and symptoms of immune system problems that can happen with Tecentriq. Patients should call or see their healthcare provider right away for any new or worse signs or symptoms, including:
- Chest pain, irregular heartbeat, shortness of breath, or swelling of ankles
- Confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs
- Double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight
- Persistent or severe muscle pain or weakness, muscle cramps
- Low red blood cells, bruising
Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include:
- chills or shaking
- itching or rash
- flushing
- shortness of breath or wheezing
- dizziness
- feeling like passing out
- fever
- back or neck pain
Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if patients undergo transplantation either before or after being treated with Tecentriq. A healthcare provider will monitor for these complications.
Getting medical treatment right away may help keep these problems from becoming more serious. A healthcare provider will check patients for these problems during their treatment with Tecentriq. A healthcare provider may treat patients with corticosteroid or hormone replacement medicines. A healthcare provider may also need to delay or completely stop treatment with Tecentriq if patients have severe side effects.
Before receiving Tecentriq, patients should tell their healthcare provider about all of their medical conditions, including if they:
- have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus
- have received an organ transplant
- have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
- have received radiation treatment to their chest area
- have a condition that affects their nervous system, such as myasthenia gravis or Guillain-Barré syndrome
-
are pregnant or plan to become pregnant. Tecentriq can harm an unborn baby. Patients should tell their healthcare provider right away if they become pregnant or think they may be pregnant during treatment with Tecentriq. Females who are able to become pregnant:
- A healthcare provider should do a pregnancy test before they start treatment with Tecentriq
- They should use an effective method of birth control during their treatment and for at least 5 months after the last dose of Tecentriq
- are breastfeeding or plan to breastfeed. It is not known if Tecentriq passes into the breast milk. Patients should not breastfeed during treatment and for at least 5 months after the last dose of Tecentriq.
Patients should tell their healthcare provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
The most common side effects of Tecentriq when used alone include:
- feeling tired or weak
- decreased appetite
- nausea
- cough
- shortness of breath
The most common side effects of Tecentriq when used in lung cancer with other anti-cancer medicines include:
- feeling tired or weak
- nausea
- hair loss
- constipation
- diarrhea
- decreased appetite
Tecentriq may cause fertility problems in females, which may affect the ability to have children. Patients should talk to their healthcare provider if they have concerns about fertility.
These are not all the possible side effects of Tecentriq. Patients should ask their healthcare provider or pharmacist for more information about the benefits and side effects of Tecentriq.
Report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. Report side effects to Genentech at 1-888-835-2555.
Please see http://www.Tecentriq.com for full Prescribing Information and additional Important Safety Information.
About Genentech
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241125394901/en/
Media Contact:
Nicolette Baker (650) 467-6800
Advocacy Contact:
Meg Harrison (617) 694-7060
Investor Contacts:
Loren Kalm (650) 225-3217
Bruno Eschli +41616875284
Source: Genentech
FAQ
What was the outcome of Roche's (RHHBY) SKYSCRAPER-01 Phase III trial?
How many patients were enrolled in Roche's (RHHBY) SKYSCRAPER-01 study?
When will Roche (RHHBY) present detailed SKYSCRAPER-01 trial data?
What was the safety profile of tiragolumab in Roche's (RHHBY) SKYSCRAPER-01 study?
